Oncolytics Biotech Inc.

ONCY • Biotechnology

$0.84

▼ -0.01 (-1.55%)

Current price

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$100.96M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:10 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.84

Change-1.55%

Shares Out119.74M

Market Cap$100.96M

Enterprise Value$97.30M

52W Range0.73 - 1.51

Beta1.14

P/E-2.60

P/B-16.37

P/FCF-3.29

EV/EBITDA-2.44

EV/FCF-3.17

Price$0.84

Change-1.55%

Shares Out119.74M

Market Cap$100.96M

Enterprise Value$97.30M

52W Range0.73 - 1.51

Beta1.14

P/E-2.60

P/B-16.37

P/FCF-3.29

EV/EBITDA-2.44

EV/FCF-3.17

Earnings Yield-38.43%

FCF Yield-30.39%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq-0.15

Current Ratio1.12

Quick Ratio1.12

Volume1.12M

Avg Volume1.33M

EPS Surprise-0.03

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

49/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

50/100

Why this score▼

Weak profitability

Analyst view

Analyst sentiment and price target

ONCY

Analyst sentiment

Based on 10 analyst votes · 2026-09-05

90/100

Bullish

Hold

Bearish

Company Overview

IPO: 10/5/2001

Industry: Biotechnology

P/B i: -16.37

Debt / Equity i: -0.15

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score10 / 20

Debt / Equity: -0.15

Current Ratio: 1.12

Quick Ratio: 1.12

Status: Moderate

Insider Transactions

Recent executive and insider activity

Glover Stephen C.

Transaction: 06/01/2026

OTHER

Change

Price

Not reported

Filing

06/03/2026

Type

OTHER

McAdory John Bearden

Transaction: 06/01/2026

OTHER

Change

+500,000

Price

$0.97

Filing

06/03/2026

Type

OTHER

Kelly Jared

Transaction: 03/12/2026

BUY

Change

+5,050

Price

$0.96

Filing

03/13/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Glover Stephen C.	OTHER	0	Not reported	06/01/2026	06/03/2026
McAdory John Bearden	OTHER	+500,000	$0.97	06/01/2026	06/03/2026
Kelly Jared	BUY	+5,050	$0.96	03/12/2026	03/13/2026
Parsons James T.	BUY	+10,000	$1.03	03/11/2026	03/13/2026
Andrews Patricia S	BUY	+35,400	$0.86	02/12/2026	02/13/2026
Seizinger Bernd R.	BUY	+40,000	$0.85	02/12/2026	02/13/2026
Hagerman Allison	BUY	+10,000	$0.83	02/12/2026	02/13/2026
Brown Deborah Margaret	BUY	+25,000	$0.85	02/12/2026	02/13/2026
Heineman Thomas Charles	BUY	+12,132	$0.83	02/12/2026	02/13/2026
Pisano Wayne	BUY	+30,000	$0.84	02/12/2026	02/13/2026
Look Kirk	BUY	+12,000	$0.84	02/12/2026	02/13/2026
Kelly Jared	BUY	+29,500	$0.84	02/12/2026	02/13/2026
Aromando Andrew	BUY	+29,600	$0.86	02/11/2026	02/13/2026
Seizinger Bernd R.	BUY	+60,000	$0.83	02/11/2026	02/13/2026
Kelly Jared	BUY	+5,600	$0.84	02/11/2026	02/13/2026
Seizinger Bernd R.	BUY	+100,000	$1.04	01/16/2026	01/20/2026
RIGBY JONATHAN	OTHER	+45,000	$1.84	01/01/2026	01/02/2026
RIGBY JONATHAN	OTHER	0	Not reported	01/01/2026	01/02/2026
Aromando Andrew	OTHER	+250,000	$0.99	01/01/2026	01/02/2026
Aromando Andrew	OTHER	0	Not reported	01/01/2026	01/02/2026

About the Company

Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Source - link

Peers

ATOS CLNN COYA IMMX MGNX SRZN TIL TVGN WHWK ZNTL

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has received written feedback from the U.S. Food and Drug Administration (“FDA”) regarding the design of a potential pivotal Part B expansion of REO 033, the Company's ongoing randomized study evaluating pelareorep in second-line RAS-mutant, microsatellite stable (“MSS”) metastatic colorectal cancer (“REO 033”). The Company submitted a Type D meeting request to the FDA regarding the potential expansion of REO 033 into a pivotal study.

GlobeNewsWire

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track designation in gastrointestinal cancers strengthens Oncolytics' regulatory momentum and continues to advance the Company's path toward registration SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal (“SCAC”) who have progressed on or were intolerant to one or more prior lines of systemic therapy. Fast Track designation is intended to facilitate the development and expedite the review of therapies that treat serious diseases and address significant unmet medical needs.

GlobeNewsWire

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design Part B will be a randomized study designed to support potential accelerated and full approval SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today provided a clinical and regulatory update on REO 033, the Company's randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan (“FOLFIRI”) and bevacizumab for the second-line treatment of patients with Rat Sarcoma (“RAS”)-mutant, microsatellite stable (“MSS”) metastatic colorectal cancer. REO 033 builds upon the previously reported REO 022 study, which more than doubled historical standard-of-care benchmarks across progression-free survival, overall survival, duration of response, and objective response rate.1 -4 Based on these data, pelareorep has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for this indication.

GlobeNewsWire

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Intellectual property update confirms pelareorep's unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a new patent broadly protecting the Company's proprietary manufacturing process for pelareorep. The newly issued patent covers key aspects of the methods used to manufacture pelareorep and is expected to provide intellectual property protection into 2044.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-0.05	-0.08	-0.03
2026-03-30	-0.06	-0.08	-0.02
2025-11-12	-0.12	-0.1	0.02
2025-08-08	-0.11	-0.05	0.06
2025-05-14	-0.09	-0.06	0.03
2025-03-07	-0.08	-0.07	0.01
2024-11-12	-0.08	-0.09	-0.01
2024-08-01	-0.08	-0.07	0.01
2024-05-09	-0.09	-0.07	0.02
2024-03-07	-0.11	-0.04	0.07
2023-11-03	-0.07	-0.1	-0.03
2023-08-14	-0.09	-0.09	0